Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9


Pharmacokinetics of an antiretroviral regimen in a patient unable to swallow solid oral dosage forms.

Patti F, Calcagno A, Simiele M, Bonasso M, Di Perri G, D'Avolio A, Bonora S.

Am J Health Syst Pharm. 2016 Jun 1;73(11):750-4. doi: 10.2146/ajhp150861. No abstract available.


Neonatal Near Miss: the need for a standard definition and appropriate criteria and the rationale for a prospective surveillance system.

Santos JP, Cecatti JG, Serruya SJ, Almeida PV, Duran P, Mucio Bd, Pileggi-Castro C; PAHO Neonatal Near Miss Working Group.

Clinics (Sao Paulo). 2015 Dec;70(12):820-6. doi: 10.6061/clinics/2015(12)10. Review.


Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage.

Calcagno A, Bonora S, Simiele M, Rostagno R, Tettoni MC, Bonasso M, Romito A, Imperiale D, D'Avolio A, Di Perri G.

AIDS. 2011 Jul 17;25(11):1437-9. doi: 10.1097/QAD.0b013e3283489cb1. No abstract available.


Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction.

Data Collection on Adverse Events of Anti-HIV Drugs Study Group, Sabin CA, d'Arminio Monforte A, Friis-Moller N, Weber R, El-Sadr WM, Reiss P, Kirk O, Mercie P, Law MG, De Wit S, Pradier C, Phillips AN, Lundgren JD.

Clin Infect Dis. 2008 Apr 1;46(7):1101-10. doi: 10.1086/528862.


Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.

D:A:D Study Group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD.

Lancet. 2008 Apr 26;371(9622):1417-26. doi: 10.1016/S0140-6736(08)60423-7. Epub 2008 Apr 2. Erratum in: Lancet. 2008 Jul 26;372(9635):292.


The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon.

Aguilar Marucco D, Gonzalez de Requena D, Bonora S, Tettoni C, Bonasso M, De Blasi T, D'Avolio A, Sciandra M, Siccardi M, Baietto L, Trentini L, Sinicco A, Cariti G, Di Perri G.

J Antimicrob Chemother. 2008 Apr;61(4):919-24. doi: 10.1093/jac/dkn013. Epub 2008 Jan 31.


Recent acquired STD and the use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): analysis of the incidence of newly acquired hepatitis B infection and syphilis.

Cicconi P, Cozzi-lepri A, Orlando G, Matteelli A, Girardi E, Degli Esposti A, Moioli C, Rizzardini G, Chiodera A, Ballardini G, Tincati C, d'Arminio Monforte A; I.Co.N.A. Study Group.

Infection. 2008 Feb;36(1):46-53. doi: 10.1007/s15010-007-6300-z. Epub 2008 Jan 29.


The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug?

Puoti M, Cozzi-Lepri A, Ancarani F, Bruno R, Ambu S, Ferraro T, Tundo P, Santantonio T, Toti M, Bonasso M, d'Arminio Monforte A; HepaI.CoNA Study Group; ICoNA Study Group.

Antivir Ther. 2004 Oct;9(5):811-7.


Imipenem/cilastatin as empirical treatment of severe infections in compromised patients.

Biglino A, Bonasso M, Gioannini P.

J Chemother. 1991 Jan;3 Suppl 1:208-12.


Supplemental Content

Loading ...
Support Center